Telehealth Ketamine for Substance Use Disorders: Emerging Programs and Cautions

Telehealth ketamine for substance use disorders is an emerging but narrowly appropriate treatment path, not a general prescription available to everyone with an addiction diagnosis. The strongest evidence supports ketamine for alcohol use disorder (AUD), with smaller trials suggesting possible benefit for cocaine use disorder, opioid use disorder, and nicotine dependence. Because ketamine itself carries misuse potential, most telehealth platforms exclude active alcohol use disorder, active stimulant use disorder, unmanaged opioid use disorder, and any history of ketamine or dissociative drug misuse. Safe use in this population depends on rigorous screening, coordination with addiction treatment providers, and safeguards that are harder to enforce in an unsupervised at-home model than in a clinical setting. This guide covers what the research shows, who is a realistic candidate, and what a responsible telehealth program requires before prescribing ketamine to someone with a substance use history.

Substance use disorders and depression share overlapping biology: impaired reward circuitry, reduced neuroplasticity, and dysregulation of the brain's glutamate system. Ketamine, an NMDA receptor antagonist (PubChem compound summary), works through N-methyl-D-aspartate (NMDA) receptor blockade followed by a surge in brain-derived neurotrophic factor (BDNF), a protein that supports neuron growth and new synaptic connections. This is the same pathway thought to drive ketamine's antidepressant effects (see StatPearls' clinical overview of ketamine pharmacology). Researchers have proposed several ways this mechanism could apply to addiction:

• Disrupting maladaptive memory consolidation. Addiction involves strong learned associations between cues and craving. Ketamine given around cue exposure may interfere with how those memories get reconsolidated.
• Supporting new learning. The BDNF surge may make it easier to form new, healthier behavioral associations that compete with addiction-maintaining ones.
• Reducing craving acutely. Some studies report lower craving in the hours to days following a ketamine infusion.
• Treating co-occurring depression. Addressing depression removes a major driver of relapse (see our guide on next steps for treatment-resistant depression).

According to the World Health Organization, depression affects an estimated 5 percent of adults worldwide, which matters here because co-occurring depression is a well-documented driver of relapse in substance use disorders.

The evidence for ketamine in substance use disorders varies considerably by substance, and none of it currently supports unsupervised at-home dosing as a stand-alone addiction treatment.

Alcohol use disorder (AUD) has the strongest evidence base. A 2019 randomized controlled trial by Dakwar and colleagues found that a single IV ketamine infusion combined with mindfulness-based therapy produced significantly higher abstinence rates than midazolam plus the same therapy. A UK trial known as KARE similarly found that ketamine paired with psychological therapy outperformed standard treatment.

Cocaine use disorder has smaller studies and case series suggesting ketamine may reduce craving and use, though the evidence base is less robust than for AUD.

Opioid use disorder (OUD) research is more cautious because ketamine and opioids interact pharmacologically and share some dissociative and sedative risk. Some studies suggest benefit, particularly in patients with co-occurring depression, but this application is mostly confined to academic research settings.

Nicotine dependence has only very preliminary evidence from a small trial suggesting ketamine may support smoking cessation attempts.

Ketamine is itself a substance with misuse potential, so using it to treat addiction creates an obvious tension. In an in-person clinical setting, this is managed through close monitoring, limited dispensing, and direct clinical observation. In an at-home telehealth model, those safeguards are reduced, which is a major reason responsible platforms restrict eligibility so tightly. For more on the risks unsupervised at-home ketamine use can create, see our reporting on oversight concerns at online ketamine sellers.

Telehealth ketamine for substance use disorders is not appropriate for every patient with an SUD diagnosis. Most platforms exclude:

• Active alcohol use disorder. Combining alcohol and ketamine is dangerous because of anesthetic interaction and combined central nervous system depression. Some platforms require a documented sobriety period before considering enrollment.
• Active stimulant use disorder. Stimulants and ketamine have cardiovascular interactions that are difficult to monitor remotely.
• Active ketamine or dissociative misuse history, an absolute contraindication (see above).
• Active, unmanaged opioid use disorder. Patients without medical treatment for OUD are not appropriate for at-home ketamine without extensive additional safeguards.

Patients who may be reasonable candidates typically include those with alcohol use disorder in sustained recovery and comorbid depression, patients with nicotine or cannabis use disorder whose primary current diagnosis is depression or anxiety, and patients whose substance use is in stable remission with a depressive or anxiety disorder as the active treatment target.

A small number of addiction medicine specialists have begun integrating ketamine into structured SUD treatment, though these remain primarily in-person programs with limited telehealth components for follow-up care:

• Academic medical centers running IRB-approved ketamine trials for AUD, where clinical trial participation may be available.
• Addiction psychiatry practices that use ketamine as an adjunct to medication-assisted treatment (MAT) for appropriate patients.
• Integration-focused programs that combine ketamine with intensive motivational interviewing and relapse prevention counseling.

As of 2026, these structured programs are not available at scale through consumer telehealth platforms. For background on how telehealth ketamine prescribing works more broadly, see our telehealth legality overview and our article on oversight concerns at online ketamine sellers.

Using a dissociative substance to treat addiction raises legitimate questions: whether regular ketamine use in an addiction-treatment context carries its own dependency risk, and how programs ensure harm-reduction goals are met rather than undermined. Most practitioners in this space address these questions with structured, time-limited protocols rather than indefinite ongoing prescribing, mandatory therapy integration, strict exclusion of patients with a ketamine misuse history, and regular reassessment of the benefit-to-risk ratio. These safeguards matter more in this population than in most other ketamine therapy applications.

Sources

• StatPearls: Ketamine - clinical reference on ketamine pharmacology and mechanisms of action.
• PubChem: Ketamine Compound Summary - NCBI chemical database entry with pharmacokinetic and bioactivity data.
• MedlinePlus: Ketamine - National Library of Medicine consumer drug information on uses, administration, and precautions.
• NIMH: Depression - National Institute of Mental Health overview of depressive disorders and emerging treatments.
• WHO: Depression Fact Sheet - World Health Organization data on depression prevalence and treatment.